SGLT2 inhibitor trials for empagliflozin (EMPA-REG OUTCOME), canagliflozin (CANVAS program), dapagliflozin (DECLARE-TIMI 58 and DAPA-HF), and ertugliflozin (VERTIS-CV) have demonstrated success in cardiovascular outcomes. Here, SLC5A2 is linked to hydrops fetalis.